1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022

Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022

  • March 2016
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 452 pages

Way back to the history, over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide’s and radiolabeled compounds. This advancement has majorly impacted the health care practice. In the present scenario nuclear medicine is considered to be one of the diagnostics and therapeutic modality technique for probing, tracking and treating disease-related tissue function, progression and treatment response. Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.

Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.
According to IQ4I analysis, the global nuclear medicine/radiopharmaceutical market is expected to reach 9,275.3 million by 2022. Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

The SPECT and PET diagnostics market is further divided into isotopes and application. SPECT market by isotopes includes technetium (Tc-99m), thallium (Tl-201), gallium (Ga-67), iodine (I-123), samarium (Sm-153), yttrium (Y-90), rhenium (Re-186) and others. SPECT by applications are classified into cardiology, gastro intestinal, oncology, nephrology, neurology, inflammation, thyroid glands, lymphology and others. The PET diagnostic market by isotopes involves fluorodeoxyglucose (18f-FDG), gallium (Ga-68), rubidium (Rb-82) and others. PET applications are segmented into cardiology, oncology, neurology, inflammation, thyroid and others.

The alpha radiation therapy includes actinium (Ac-225), astatine-211 (At-211), lead (Pb-212)/bismuth (Bi-212), radium (Ra-223), radium-224 (Ra-224), thorium-227 (Th-227) and others. The isotopes considered in beta radiation therapy are erbium (Er-169), iodine (I-131) lutetium (Lu-177), rhenium (Re-186), samarium (Sa-153), strontium (Sr-89), yttrium (Y-90) and others. The final therapeutic segment brachytherapy involves cesium (Cs-131), iodine (I-125), iridium (Ir-192), palladium (Pd-103) and others

The nuclear medicine market end-users include medical, academic research laboratories and industries. The end-users by medical further segmented into hospitals and diagnostic centers.
The nuclear medicine/radiopharmaceutical market includes stable isotopes section as well which is classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), sulphur (S-32) and others. The stable isotopes have application in diagnostics and therapy, pharmaceutical companies, research section and industrial sector. The leading players of this market are Cambridge Isotope Laboratories (U.S) and Isotec Inc. subsidiary of Sigma Aldrich (U.S.).

The nuclear medicine/radiopharmaceuticals market is expected to grow at single digit CAGR during 2015 to 2022. The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market. In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market. The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.

The nuclear medicine/radiopharmaceuticals global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the nuclear medicine market are Bayer Healthcare (Germany) Cardinal Health Inc. (U.S.), Cambridge Isotope Laboratories (U.S), GE Healthcare (U.K.), IBA Group (Belgium), Isotec Inc. (U.S.) Lantheus Medical Imaging (U.S.), Mallinckrodt Plc (Ireland), NTP Radioisotopes (South Africa), Nordion Inc (Canada) Siemens Healthcare (Germany) and Taiyo Nippon Sanso Corporation (Japan).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Table Of Contents

Nuclear Medicine/Radiopharmaceutical Global Market - Forecast To 2022

1 EXECUTIVE SUMMARY 35
2 INTRODUCTION 40
2.1 KEY TAKE AWAYS 40
2.2 REPORT DESCRIPTION 41
2.3 MARKETS COVERED 44
2.4 STAKEHOLDERS 47
2.5 RESEARCH METHODOLOGY 47
2.5.1 MARKET SIZE ESTIMATION 49
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 51
2.5.3 SECONDARY SOURCES 52
2.5.4 KEY DATA POINTS FROM SECONDARY SOURCES 53
2.5.5 PRIMARY SOURCES 54
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 54
2.5.7 ASSUMPTIONS 54
3 MARKET ANALYSIS 56
3.1 INTRODUCTION 56
3.2 MARKET SEGMENTATION 57
3.3 FACTORS INFLUENCING MARKET 60
3.3.1 DRIVERS and OPPORTUNITIES 61
3.3.1.1 Increased application of radio pharmaceuticals 61
3.3.1.2 Rise in public awareness 62
3.3.1.3 Usage of hybrid imaging 62
3.3.1.4 Abundance of radio pharmaceuticals 63
3.3.1.5 Technological advancements 63
3.3.1.6 Increasing need in emerging markets 64
3.3.1.7 Production of radio pharmaceuticals from cyclotrons 65
3.3.1.8 Efficient diagnosis and treatments 65
3.3.1.9 Emerging radioisotopes 66
3.3.1.10 Increasing therapeutic application areas 66
3.3.1.11 Replacement of old/traditional equipment 67
3.3.2 RESTRAINTS and THREATS 67
3.3.2.1 Regulatory issues 67
3.3.2.2 High cost and supply shortage of isotopes 68
3.3.2.3 Shorter half-life of radiopharmaceuticals 69
3.3.2.4 Threat from traditional/alternative diagnostic procedures 69
3.3.2.5 Huge capital investment 70
3.3.2.6 Shortage of qualified technicians 70
3.3.2.7 Radio toxicity 71
3.4 PROBLEM AREAS 72
3.4.1 CLOSURE OF REACTORS 72
3.5 WINNING IMPERATIVES 72
3.5.1 AVAILABILITY OF TECHNETIUM 72
3.6 REGULATORY GUIDELINES 73
3.6.1 UNITED STATES 73
3.6.2 EUROPE 74
3.6.3 JAPAN 74
3.6.4 CHINA 75
3.6.5 SOUTH KOREA 76
3.7 REIMBURSEMENT SCENARIO and CHALLENGES 76
3.8 PATENT TRENDS 88
3.9 SUPPLY CHAIN ANALYSIS 91
3.9.1 REACTORS 91
3.9.2 PROCESSING FACILITY 92
3.9.3 GENERATORS MANUFACTURING UNITS 93
3.9.4 HOSPITALS AND CENTRAL RADIO PHARMACIES 93
3.10 LIST OF POTENTIAL NEW REACTORS 94
3.11 PORTER'S FIVE FORCE ANALYSIS 96
3.11.1 THREAT OF NEW ENTRANTS 96
3.11.2 THREAT OF SUBSTITUTES 97
3.11.3 BARGAINING POWER OF SUPPLIERS 97
3.11.4 BARGAINING POWER OF BUYERS 97
3.11.5 COMPETITIVE RIVALRY 98
3.12 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 99
3.12.1 NUCLEAR MEDICINE MARKET 99
3.12.2 STABLE ISOTOPES MARKET 102
4 RADIOPHARMACEUTICALS BY TYPE 104
4.1 INTRODUCTION 104
4.2 DIAGNOSTICS 106
4.2.1 RADIOPHARMACEUTICALS FOR DIAGNOSIS, BY ISOTOPES 111
4.2.1.1 SPECT, by isotopes 111
4.2.1.1.1 Technetium (Tc-99m) 114
4.2.1.1.2 Thallium (Tl-201) 116
4.2.1.1.3 Gallium (Ga-67) 118
4.2.1.1.4 Iodine (I-123) 119
4.2.1.1.5 Samarium (Sm-153) 121
4.2.1.1.6 Yttrium (Y-90) 122
4.2.1.1.7 Rhenium (Re-186) 124
4.2.1.1.8 Others 125
4.2.1.2 PET, by isotopes 127
4.2.1.2.1 Fluorodeoxyglucose (FDG) 128
4.2.1.2.2 Gallium (Ga-68) 130
4.2.1.2.3 Rubidium (Rb-82) 133
4.2.1.2.4 Others 134
4.2.2 RADIOPHARMACEUTICALS FOR DIAGNOSIS, BY APPLICATION 136
4.2.2.1 SPECT by application 136
4.2.2.1.1 Cardiology 138
4.2.2.1.2 Gastro intestinal 140
4.2.2.1.3 Oncology 141
4.2.2.1.4 Nephrology 143
4.2.2.1.5 Neurology 144
4.2.2.1.6 Inflammation 145
4.2.2.1.7 Thyroid glands 146
4.2.2.1.8 Lymphology 148
4.2.2.1.9 Others 149
4.2.2.2 PET by application 151
4.2.2.2.1 Oncology 152
4.2.2.2.2 Neurology 153
4.2.2.2.3 Cardiology 155
4.2.2.2.4 Inflammation 156
4.2.2.2.5 Others 157
4.3 THERAPEUTICS 159
4.3.1 RADIOPHARMACEUTICALS FOR THERAPEUTICS, BY TYPE 160
4.3.1.1 Beta radiation therapy 162
4.3.1.1.1 Yttrium (Y-90) 165
4.3.1.1.2 Iodine (I-131) 167
4.3.1.1.3 Lutetium (Lu-177) 169
4.3.1.1.4 Samarium (Sm-153) 171
4.3.1.1.5 Rhenium (Re-186) 173
4.3.1.1.6 Strontium (Sr-89) 175
4.3.1.1.7 Erbium (Er-169) 177
4.3.1.1.8 Others 179
4.3.1.2 Alpha radiation therapy, by isotopes 181
4.3.1.2.1 Actinium (Ac-225) 182
4.3.1.2.2 Astatine (At-211) 182
4.3.1.2.3 Lead (Pb-212)/Bismuth (Bi-212) 183
4.3.1.2.4 Radium-224 183
4.3.1.2.5 Radium-223 184
4.3.1.2.6 Thorium-227 (Th-227) 184
4.3.1.2.7 Others 185
4.3.1.3 Brachytherapy, by isotopes 186
4.3.1.3.1 Iodine (I-125) 189
4.3.1.3.2 Cesium (Cs-131) 191
4.3.1.3.3 Iridium (Ir-192) 193
4.3.1.3.4 Palladium (Pd-103) 195
4.3.1.3.5 Others 197
4.3.2 Therapeutics radiopharmaceuticals, by application 198
4.3.2.1 Oncology 200
4.3.2.2 Nephrology 202
4.3.2.3 Cardiology 204
4.3.2.4 Neurology 205
4.3.2.5 Others 207
5 GLOBAL NUCLEAR MEDICINE MARKET BY END-USERS 209
5.1 INTRODUCTION 209
5.2 MEDICAL 213
5.2.1 HOSPITALS 214
5.2.2 DIAGNOSTIC CENTERS 216
5.3 ACADEMIC RESEARCH LABORATORIES 218
5.4 INDUSTRIES 220
6 STABLE ISOTOPES 222
6.1 INTRODUCTION 222
6.2 MARKET ANALYSIS 223
6.2.1 FACTORS INFLUENCING MARKET 223
6.2.2 DRIVERS and OPPORTUNITIES 224
6.2.2.1 Increased use as controlled drug standards 224
6.2.2.2 Increasing medical applications (diagnostics and therapeutics) 224
6.2.2.3 Increased usage in personalized medicine and PK studies 224
6.2.2.4 System biology and proteomics applications 225
6.2.2.5 Ecological and environmental studies 225
6.2.3 RESTRAINTS AND THREATS 225
6.2.3.1 High cost of stable isotopes 225
6.2.3.2 Stable isotopes-side effects 226
6.2.3.3 Safety issues of deuterium 226
6.3 STABLE ISOTOPES MARKET, BY ISOTOPE 227
6.3.1 Carbon (C-13) 230
6.3.2 Deuterium (D2) 232
6.3.3 Oxygen (O-18) 234
6.3.4 Nitrogen (N-15) 236
6.3.5 Sulfur (S-32) 238
6.3.6 Others 239
6.4 STABLE ISOTOPES MARKET, BY APPLICATION 241
6.4.1 DIAGNOSTICS AND THERAPY 243
6.4.2 PHARMACEUTICALS 245
6.4.3 RESEARCH 247
6.4.4 INDUSTRIAL SECTOR 249
6.5 STABLE ISOTOPES MARKET, BY GEOGRAPHY 251
6.5.1 INTRODUCTION 251
6.5.2 NORTH AMERICA 253
6.5.3 EUROPE 257
6.5.4 ASIA-PACIFIC 261
6.5.5 REST OF THE WORLD 265
7 REGIONAL ANALYSIS 269
7.1 INTRODUCTION 269
7.2 NORTH AMERICA 272
7.3 EUROPE 289
7.4 ASIA-PACIFIC 306
7.5 REST OF THE WORLD 323
8 COMPETITIVE LANDSCAPE 340
8.1 INTRODUCTION 340
8.2 NEW PRODUCT LAUNCHES 341
8.3 AGREEMENTS, PARTNERSHIP, COLLABORATION and JOINT VENTURES 346
8.4 APPROVALS 354
8.5 EXPANSIONS 357
8.6 MERGERS and ACQUISITIONS 358
8.7 OTHER DEVELOPMENTS 361
9 MAJOR PLAYER PROFILES 363
9.1 BAYER HEALTHCARE 363
9.1.1 OVERVIEW 363
9.1.2 FINANCIALS 364
9.1.3 PRODUCT PORTFOLIO 367
9.1.4 KEY DEVELOPMENTS 367
9.1.5 BUSINESS STRATEGY 368
9.1.6 SWOT ANALYSIS 369
9.2 CARDINAL HEALTH INC. 370
9.2.1 OVERVIEW 370
9.2.2 FINANCIALS 371
9.2.3 PRODUCT PORTFOLIO 374
9.2.4 KEY DEVELOPMENTS 375
9.2.5 BUSINESS STRATEGY 377
9.2.6 SWOT ANALYSIS 378
9.3 CAMBRIDGE ISOTOPE LABORATORIES INC. 379
9.3.1 OVERVIEW 379
9.3.2 FINANCIALS 379
9.3.3 PRODUCT PORTFOLIO 380
9.3.4 KEY DEVELOPMENTS 381
9.3.5 BUSINESS STRATEGY 382
9.3.6 SWOT ANALYSIS 383
9.4 GE HEALTHCARE 384
9.4.1 OVERVIEW 384
9.4.2 FINANCIALS 385
9.4.3 PRODUCT PORTFOLIO 388
9.4.4 KEY DEVELOPMENTS 388
9.4.5 BUSINESS SRATEGY 391
9.4.6 SWOT ANALYSIS 392
9.5 IBA GROUP 393
9.5.1 OVERVIEW 393
9.5.2 FINANCIALS 394
9.5.3 PRODUCT PORTFOLIO 397
9.5.4 KEY DEVELOPMENTS 398
9.5.5 BUSINESS STRATEGY 399
9.5.6 SWOT ANALYSIS 400
9.6 ISOTEC INC 401
9.6.1 OVERVIEW 401
9.6.2 FINANCIALS 402
9.6.3 PRODUCT PORTFOLIO 404
9.6.4 KEY DEVELOPMENTS 406
9.6.5 BUSINESS STRATEGY 407
9.6.6 SWOT ANALYSIS 408
9.7 LANTHEUS MEDICAL IMAGING INC. 409
9.7.1 OVERVIEW 409
9.7.2 FINANCIALS 410
9.7.3 PRODUCT PORTFOLIO 413
9.7.4 KEY DEVELOPMENTS 413
9.7.5 BUSINESS STRATEGY 415
9.7.6 SWOT ANALYSIS 416
9.8 MALLINCKRODT PLC 417
9.8.1 OVERVIEW 417
9.8.2 FINANCIALS 418
9.8.3 PRODUCT PORTFOLIO 420
9.8.4 KEY DEVELOPMENTS 421
9.8.5 BUSINESS STRATEGY 423
9.8.6 SWOT ANALYSIS 424
9.9 NORDION INC 425
9.9.1 OVERVIEW 425
9.9.2 FINANCIALS 425
9.9.3 PRODUCT PORTFOLIO 426
9.9.4 KEY DEVELOPMENTS 427
9.9.5 BUSINESS STRATEGY 428
9.9.6 SWOT ANALYSIS 429
9.10 NTP RADIOISOTOPES SOC LTD 430
9.10.1 OVERVIEW 430
9.10.2 FINANCIALS 430
9.10.3 PRODUCT PORTFOLIO 431
9.10.4 KEY DEVELOPMENTS 432
9.10.5 BUSINESS STRATEGY 433
9.10.6 SWOT ANALYSIS 434
9.11 SIEMENS HEALTHCARE 435
9.11.1 OVERVIEW 435
9.11.2 FINANCIALS 436
9.11.3 PRODUCT PORTFOLIO 438
9.11.4 KEY DEVELOPMENTS 439
9.11.5 BUSINESS STRATEGY 441
9.11.6 SWOT ANALYSIS 442
9.12 TAIYO NIPPON SANSO CORPORATION 443
9.12.1 OVERVIEW 443
9.12.2 FINANCIALS 444
9.12.3 PRODUCT PORTFOLIO 446
9.12.4 KEY DEVELOPMENTS 447
9.12.5 BUSINESS STRATEGY 450
9.12.6 SWOT ANALYSIS 451

















LIST OF TABLES

TABLE 1 NUCLEAR MEDICINE GLOBAL MARKET REVENUE BY REGION,
(2014-2022) ($MN) 39
TABLE 2 REIMBURSEMENT RATES FOR BONE SCANS IN UNITED STATES 78
TABLE 3 REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES 79
TABLE 4 TECHNETIUM (TC-99M) REACTORS 92
TABLE 5 NEW POTENTIAL REACTORS 95
TABLE 6 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY TYPE,
(2014-2022) ($MN) 106
TABLE 7 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 108
TABLE 8 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 109
TABLE 9 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 110
TABLE 10 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE,
(2014-2022) ($MN) 113
TABLE 11 SPECT TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 116
TABLE 12 SPECT THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 117
TABLE 13 SPECT GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 119
TABLE 14 SPECT IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 120
TABLE 15 SPECT SAMARIM (SM-153) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 122
TABLE 16 SPECT YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 123
TABLE 17 SPECT RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 125
TABLE 18 SPECT OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 126
TABLE 19 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPES,
(2014-2022) ($MN) 128
TABLE 20 PET FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 130
TABLE 21 PET GALLIUM (GA-68) GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 132
TABLE 22 PET RUBIDIUM (RB-82) GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 134
TABLE 23 PET OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 135
TABLE 24 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 137
TABLE 25 SPECT CARDIOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 139
TABLE 26 SPECT GASTROINTESTINAL APPLICATION GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 141
TABLE 27 SPECT ONCOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 142
TABLE 28 SPECT NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 143
TABLE 29 SPECT NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 145
TABLE 30 SPECT INFLAMMATION APPLICATION GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 146
TABLE 31 SPECT THYROID GLANDS APPLICATION GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 147
TABLE 32 SPECT LYMPHOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 148
TABLE 33 SPECT OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 150
TABLE 34 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 152
TABLE 35 PET ONCOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 153
TABLE 36 PET NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 154
TABLE 37 PET CARDIOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 156
TABLE 38 PET INFLAMMATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 157
TABLE 39 PET INFLAMMATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 158
TABLE 40 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 161
TABLE 41 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 163
TABLE 42 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY ISOTOPES, (2014-2022) ($MN) 164
TABLE 43 BETA RADIATION THERAPY YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 166
TABLE 44 BETA RADIATION THERAPY IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 168
TABLE 45 BETA RADIATION THERAPY LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 170
TABLE 46 BETA RADIATION THERAPY SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 172
TABLE 47 BETA RADIATION THERAPY RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 174
TABLE 48 BETA RADIATION THERAPY STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 176
TABLE 49 BETA RADIATION THERAPY ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 178
TABLE 50 BETA RADIATION THERAPY OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 180
TABLE 51 ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 181
TABLE 52 BRACHYTHERAPY GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 187
TABLE 53 BRACHYTHERAPY GLOBAL MARKET REVENUE, BY ISOTOPES,
(2014-2022) ($MN) 188
TABLE 54 BRACHYTHERAPY IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 190
TABLE 55 BRACHYTHERAPY CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 192
TABLE 56 BRACHYTHERAPY IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 194
TABLE 57 BRACHYTHERAPY PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 196
TABLE 58 BRACHYTHERAPY OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 197
TABLE 59 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY APPLICATION,
(2014-2022) ($MN) 199
TABLE 60 NUCLEAR MEDICINE THERAPEUTICS ONCOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 201
TABLE 61 NUCLEAR MEDICINE THERAPEUTICS NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 203
TABLE 62 NUCLEAR MEDICINE THERAPEUTICS CARDIOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 204
TABLE 63 NUCLEAR MEDICINE THERAPEUTICS NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 206
TABLE 64 NUCLEAR MEDICINE THERAPEUTICS OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 208
TABLE 65 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY END-USERS,
(2014-2022) ($MN) 211
TABLE 66 NUCLEAR MEDICINE (MEDICAL) END-USERS GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 212
TABLE 67 NUCLEAR MEDICINE (MEDICAL) END-USERS GLOBAL MARKET REVENUE,
BY TYPE, (2014-2022) ($MN) 214
TABLE 68 NUCLEAR MEDICINE HOSPITAL END-USERS GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 215
TABLE 69 NUCLEAR MEDICINE DIAGNOSTIC CENTRES END-USER GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 217
TABLE 70 NUCLEAR MEDICINE ACADEMIC RESEARCH LABORATORIES END-USER GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 219
TABLE 71 NUCLEAR MEDICINE INDUSTRIES END-USER GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 221
TABLE 72 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 228
TABLE 73 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY ISOTOPE,
(2014-2022) ($MN) 229
TABLE 74 STABLE ISOTOPES CARBON (C-13) GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 231
TABLE 75 STABLE ISOTOPES DEUTERIUM (D2) GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 233
TABLE 76 STABLE ISOTOPES OXYGEN (O-18) GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 235
TABLE 77 STABLE ISOTOPES NITROGEN (N-15) GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 237
TABLE 78 STABLE ISOTOPES SULFUR (S-32) GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 238
TABLE 79 STABLE OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 240
TABLE 80 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION,
(2014-2022) ($MN) 242
TABLE 81 STABLE ISOTOPES DIAGNOSTICS andTHERAPY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 244
TABLE 82 STABLE ISOTOPES PHARMACEUTICALS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 246
TABLE 83 STABLE ISOTOPES RESEARCH APPLICATION GLOBAL MARKET REVENUE,
BY REGION, (2014-2022) ($MN) 248
TABLE 84 STABLE ISOTOPES INDUSTRIAL SECTOR APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 250
TABLE 85 STABLE ISOTOPES INDUSTRIAL SECTOR APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 252
TABLE 86 NORTH AMERICAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 255
TABLE 87 NORTH AMERICAN STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 256
TABLE 88 EUROPEAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE,
(2014-2022) ($MN) 259
TABLE 89 EUROPEAN STABLE ISOTOPES MARKET REVENUE, BY APPLICATION,
(2014-2022) ($MN) 260
TABLE 90 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE,
(2014-2022) ($MN) 263
TABLE 91 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 264
TABLE 92 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 267
TABLE 93 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 268
TABLE 94 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 271
TABLE 95 NORTH AMERICAN NUCLEAR MEDICINE MARKET REVENUE, BY TYPE,
(2014-2022) ($MN) 277
TABLE 96 NORTH AMERICAN NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 278
TABLE 97 NORTH AMERICAN NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY ISOTOPE, (2014-2022) ($MN) 279
TABLE 98 NORTH AMERICAN NUCLEAR MEDICINE PET MARKET REVENUE,
BY ISOTOPE, (2014-2022) ($MN) 280
TABLE 99 NORTH AMERICAN NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 281
TABLE 100 NORTH AMERICAN NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 282
TABLE 101 NORTH AMERICAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 283
TABLE 102 NORTH AMERICAN NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 284
TABLE 103 NORTH AMERICAN NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 285
TABLE 104 NORTH AMERICAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 286
TABLE 105 NORTH AMERICAN NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2014-2022) ($MN) 287
TABLE 106 NORTH AMERICAN NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 288
TABLE 107 EUROPEAN NUCLEAR MEDICINE MARKET REVENUE, BY TYPE,
(2014-2022) ($MN) 294
TABLE 108 EUROPEAN NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 295
TABLE 109 EUROPEAN NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 296
TABLE 110 EUROPEAN NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 297
TABLE 111 EUROPEAN NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 298
TABLE 112 EUROPEAN NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 299
TABLE 113 EUROPEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY TYPE, (2014-2022) ($MN) 300
TABLE 114 EUROPEAN NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 301
TABLE 115 EUROPEAN NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE,
BY ISOTOPE, (2014-2022) ($MN) 302
TABLE 116 EUROPEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 303
TABLE 117 EUROPEAN NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS,
(2014-2022) ($MN) 304
TABLE 118 EUROPEAN NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 305
TABLE 119 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY TYPE,
(2014-2022) ($MN) 311
TABLE 120 ASIA-PACIFIC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE,
BY TYPE, (2014-2022) ($MN) 312
TABLE 121 ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 313
TABLE 122 ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 314
TABLE 123 ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 315
TABLE 124 ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 316
TABLE 125 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY TYPE, (2014-2022) ($MN) 317
TABLE 126 ASIA-PACIFIC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 318
TABLE 127 ASIA-PACIFIC NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE,
BY ISOTOPE, (2014-2022) ($MN) 319
TABLE 128 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 320
TABLE 129 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2014-2022) ($MN) 321
TABLE 130 ASIA-PACIFIC NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 322
TABLE 131 REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 328
TABLE 132 REST OF THE WORLD NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 329
TABLE 133 REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY ISOTOPE, (2014-2022) ($MN) 330
TABLE 134 REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE,
BY ISOTOPE, (2014-2022) ($MN) 331
TABLE 135 REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 332
TABLE 136 REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2014-2022) ($MN) 333
TABLE 137 REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 334
TABLE 138 REST OF THE WORLD NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 335
TABLE 139 REST OF THE WORLD NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 336
TABLE 140 REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 337
TABLE 141 REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE,
BY END-USERS, (2014-2022) ($MN) 338
TABLE 142 REST OF THE WORLD NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 339
TABLE 143 NEW PRODUCT LAUNCHES (2013-2015) 342
TABLE 144 AGREEMENTS, PARTNERSHIP, COLLABORATION and JOINT VENTURES,
(2013-2015) 347
TABLE 145 APPROVALS (2013-2015) 354
TABLE 146 EXPANSIONS (2013-2015) 357
TABLE 147 MERGERS and ACQUISITIONS (2013-2015) 359
TABLE 148 OTHER DEVELOPMENTS (2013-2015) 362
TABLE 149 BAYER HEALTHCARE: TOTAL REVENUE AND RandD EXPENSES,
(2013-2015) ($MN) 364
TABLE 150 BAYER HEALTHCARE: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN) 365
TABLE 151 BAYER HEALTHCARE: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 366
TABLE 152 CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES (2013-2015) ($MN) 371
TABLE 153 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS,
(2013-2015) ($MN) 372
TABLE 154 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
(2013-2015) ($MN) 373
TABLE 155 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND RandD EXPENSES, (2013 - 2015) ($MN) 385
TABLE 156 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENTS,
(2013-2015) ($MN) 386
TABLE 157 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
(2013 - 2015) ($BN) 387
TABLE 158 IBA GROUP: TOTAL REVENUE AND RandD EXPENSES (2013 - 2015) ($MN) 394
TABLE 159 IBA GROUP: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($MN) 395
TABLE 160 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2012 - 2014) ($MN) 396
TABLE 161 ISOTEC, INC: TOTAL REVENUE AND RandD EXPENSES (2013-2015) ($MN) 402
TABLE 162 ISOTEC, INC: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($MN) 403
TABLE 163 ISOTEC, INC: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN) 404
TABLE 164 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND RandD EXPENSES, (2013-2015) ($MN) 410
TABLE 165 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2013-2015) ($MN) 411
TABLE 166 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($MN) 412
TABLE 167 MALLINCKRODT PLC: TOTAL SALES AND RandD EXPENSES,
(2013-2015) ($MN) 418
TABLE 168 MALLINCKRODT PLC: TOTAL REVENUE, BY SEGMENTS, (2013- 2015) ($BN) 419
TABLE 169 MALLINCKRODT PLC: TOTAL REVENUE, BY GEOGRAPHY,
(2013- 2015) ($MN) 420
TABLE 170 SIEMENS AG: TOTAL REVENUE AND RandD EXPENSES, (2013-2015) ($MN) 436
TABLE 171 SIEMENS AG: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN) 437
TABLE 172 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 438
TABLE 173 TAIYO NIPPON SANSO CORPORATION: TOTAL REVENUE AND RandD EXPENSES (2013-2015) ($MN) 444
TABLE 174 TAIYO NIPPON SANSO CORPORATION: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($MN) 445
TABLE 175 TAIYO NIPPON SANSO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($MN) 446







LIST OF FIGURES

FIGURE 1 NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2014-2022) 38
FIGURE 2 NUCLEAR MEDICINE GLOBAL MARKET: RESEARCH APPROACH 48
FIGURE 3 NUCLEAR MEDICINE GLOBALMARKET: TOP-DOWN AND BOTTOM-UP APPROACH 49
FIGURE 4 NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL 50
FIGURE 5 NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION 51
FIGURE 6 NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION 58
FIGURE 7 STABLE ISOTOPES GLOBAL MARKET: MARKET SEGMENTATION 59
FIGURE 8 MARKET DYNAMICS 60
FIGURE 9 NUCLEAR MEDICINE GLOBAL MARKET: PCT PATENT FILING BY MAJOR PLAYERS (2011-2015) 89
FIGURE 10 NUCLEAR MEDICINE GLOBAL MARKET: UNITED STATES PATENT FILING BY MAJOR PLAYERS (2011-2015) 90
FIGURE 11 TECHNETIUM -99: SUPPLY CHAIN ANALYSIS 93
FIGURE 12 NUCLEAR MEDICINE MARKET: PORTER'S ANALYSIS 96
FIGURE 13 NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%) 99
FIGURE 14 STABLE ISOTOPES MARKET: MAJOR PLAYER ANALYSIS (2015) (%) 102
FIGURE 15 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY TYPE,
(2014-2022) ($MN) 105
FIGURE 16 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TYPE, (2015 V'S 2022) (%) 107
FIGURE 17 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE,
(2015 V'S 2022) ($MN) 112
FIGURE 18 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPE,
(2015 V'S 2022) ($MN) 127
FIGURE 19 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V'S 2022) ($MN) 136
FIGURE 20 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V'S 2022) ($MN) 151
FIGURE 21 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2015 V'S 2022) ($MN) 160
FIGURE 22 NUCLEAR MEDICINE BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY ISOTOPE, (2015 V'S 2022) ($MN) 162
FIGURE 23 NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET REVENUE,
BY ISOTOPE, (2015 V'S 2022) ($MN) 186
FIGURE 24 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE,
BY APPLICATION, (2015 V'S 2022) ($MN) 198
FIGURE 25 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY END-USERS,
(2014-2022) ($MN) 210
FIGURE 26 STABLE ISOTOPES MARKET: MARKET DYNAMICS 223
FIGURE 27 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY ISOTOPE, (2015) (%) 227
FIGURE 28 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION,
(2015 V'S 2022) ($MN) 241
FIGURE 29 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY GEOGRAPHY,
(2014-2022) ($MN) 251
FIGURE 30 NORTH AMERICAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES and APPLICATIONS (2015 V'S2022) ($MN) 254
FIGURE 31 EUROPEAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES and APPLICATIONS (2015 V'S 2022) ($MN) 258
FIGURE 32 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES and APPLICATIONS (2015 V'S 2022) ($MN) 262
FIGURE 33 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES and APPLICATIONS (2015-2022) ($MN) 266
FIGURE 34 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION,
(2014-2022) ($MN) 270
FIGURE 35 NORTH AMERICAN SPECT, PET MARKET REVENUE, BY ISOTOPE,
(2015 V'S 2022) ($MN) 274
FIGURE 36 NORTH AMERICAN SPECT, PET MARKET REVENUE, BY APPLICATION,
(2015 V'S 2022) ($MN) 275
FIGURE 37 NORTH AMERICAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE, BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,
(2015 V'S 2022) ($MN) 276
FIGURE 38 EUROPEAN SPECT, PET MARKET REVENUE, BY ISOTOPE,
(2015 V'S 2022) ($MN) 291
FIGURE 39 EUROPEAN SPECT, PET MARKET REVENUE, BY APPLICATION,
(2015 V'S 2022) ($MN) 292
FIGURE 40 EUROPEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY TYPE, BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,
(2015 V'S 2022) ($MN) 293
FIGURE 41 ASIA-PACIFIC SPECT, PET MARKET REVENUE, BY ISOTOPE,
(2015 V'S 2022) ($MN) 308
FIGURE 42 ASIA-PACIFIC SPECT, PET MARKET REVENUE, BY APPLICATION,
(2015 V'S 2022) ($MN) 309
FIGURE 43 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY TYPE, BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,
(2015 V'S 2022) ($MN) 310
FIGURE 44 ROW SPECT, PET MARKET REVENUE, BY ISOTOPES, (2015 V'S 2022) ($MN) 325
FIGURE 45 ROW SPECT, PET MARKET REVENUE, BY APPLICATIONS,
(2015 V'S 2022) ($MN) 326
FIGURE 46 ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE,
BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,
(2015 V'S 2022) ($MN) 327
FIGURE 47 KEY GROWTH STRATEGIES (2013 - 2015) 341
FIGURE 48 SWOT: BAYER HEALTHCARE 369
FIGURE 49 SWOT: CARDINAL HEALTH, INC. 378
FIGURE 50 SWOT: CAMBRIDGE ISOTOPE LABORATORIES INC. 383
FIGURE 51 SWOT: GE HEALTHCARE 392
FIGURE 52 SWOT: IBA GROUP 400
FIGURE 53 SWOT: ISOTEC INC 408
FIGURE 54 SWOT: LANTHEUS MEDICAL IMAGING INC. 416
FIGURE 55 SWOT: MALLINCKRODT PLC 424
FIGURE 56 SWOT: NORDION INC 429
FIGURE 57 SWOT: NTP RADIOISOTOPES SOC LTD 434
FIGURE 58 SWOT: SIEMENS HEALTHCARE 442
FIGURE 59 SWOT: TAIYO NIPPON SANSO CORPORATION 451

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Global Nuclear Medicine Market

Global Nuclear Medicine Market

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application ...

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global European ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.